Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07806773) titled 'Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer' on Sept. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Tubulis GmbH
Condition:
NSCLC
Non Small Cell Lung Cancer
Intervention:
Drug: TUB-040
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 2026
Target Sample Size: 80
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07806773
Disclai...